The cancer patient’s own drug sensitivity model: researchers from the Lothe lab and collaborators recently published a paper in Clinical Cancer Research describing ex vivo patient-derived organoids from colorectal liver metastases in a heterogeneity context.
Drs. Jarle Bruun, Kushtrim Kryeziu and Peter W. Eide (photo) were shared 1st authors , and have established the PDO lineages and drug screen analyses.
The first digital PhD defence at the Institute for Cancer Research was held on the 20th of April 2020.
Dr. Jørgen Smeby defended his thesis "Molecular subtype-dependent impact of driver mutations in colorectal cancer" submitted to the Faculty of Medicine, University of Oslo.
The work was performed in the Lothe lab at the Institute for Cancer Research.
As we enter a new year, we can look back on our scientific achievements in 2019. Dept Mol Oncol is one of six research departments at the Institute for Cancer Research, and we account for about 10% of the total staff (full-time equivalent). Harvesting from a positive working environment and active collaborations among our three research groups, we can document an upward trajectory in the volume, citation numbers, and impact of our research publications.
She has performed her work in the Lothe lab., and has been a PhD student at the Institute for Clinical Medicine, Faculty of Medicine, U of Oslo.
The thesis “Integrated genomics of colorectal cancer” included three papers of which she is the 1st author (Molecular Cancer 2017, Oncogene 2019, submitted manuscript).
The candidate held an excellent trial lecture “The gut microbiome as an emerging target for cancer therapy”, and she had a good discussion with her two opponents professors Karin Jirstrøm and Eirik Frengen (photo, candidate to the right).
Researchers Anita Sveen and Ragnhild A. Lothe at the Department of Molecular Oncology describe in collaboration with gastrointestinal oncologist Scott Kopetz at MD Anderson Cancer Centre (US) the complexity of biomarker-driven precision oncology in colorectal cancer.
Three scientists received awards for their outstanding research at a ceremony taking place at Oslo University Hospital August 23rd.
The major prize - the "Excellent Researcher Award" - went to Ole A. Andreassen. Mette Kalager and Anita Sveen both received the "Early Career Award".
In order to stimulate excellent research and draw attention to the hospital's research activity, Oslo University Hospital reward outstanding publications every half-year.
Six research groups were awarded for their excellent papers published during the second half-year of 2018 on June 7th in the large auditorium at Ullevål sykehus. Each group received NOK 50.000 for use in further research. The prize winners gave short presentations.
The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.
Professor Guro Elisabeth Lind, head of the Epigentics research group at the Department of Molecular Oncology, has been elected as new leader in "Forskerforbundet" - The Norwegian Association of Researchers, taking over January 1st 2019.
Lind is a former head of "Akademiet for yngre forskere" (The Young Academy of Norway) and has also been a local representative for Forskerforbundet. She will be the first female leader since the 80's, and replaces Petter Aaslestad, who has been in charge of the Research Association for the last six years (two periods).
"I was very much in doubt, first and foremost because I am an active researcher with a research group and exciting projects. But I am also actively engaged in research policy and could not say no to this exciting challenge", Lind says to Khrono.
The vast majority of primary prostate cancers are multifocal. The individual tumors within the prostate gland are known to have different aggressiveness and develop independently of one another, but little has been known about their genetic relationship.
Marthe Løvf and colleagues have performed the first large in-depth genomic heterogeneity study of primary prostate cancer and the results were published in the recognized journal European Urology earlier this month. The researchers performed exome sequencing of 89 tumor foci from 41 patients and demonstrated convincingly that the different foci within the same patient only exceptionally have any somatic gene mutations in common.